| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Syphilis | 21 | 2019 | 318 | 8.89 | Why? |
| Neisseria gonorrhoeae | 22 | 2019 | 142 | 8.52 | Why? |
| Gonorrhea | 22 | 2019 | 315 | 7.75 | Why? |
| Sexually Transmitted Diseases | 24 | 2019 | 694 | 4.87 | Why? |
| Ciprofloxacin | 8 | 2019 | 130 | 4.29 | Why? |
| DNA Gyrase | 8 | 2019 | 30 | 4.23 | Why? |
| Homosexuality, Male | 18 | 2019 | 1158 | 3.86 | Why? |
| Chlamydia Infections | 12 | 2019 | 248 | 3.78 | Why? |
| Chlamydia trachomatis | 14 | 2019 | 172 | 3.12 | Why? |
| Trichomonas Infections | 7 | 2019 | 24 | 2.95 | Why? |
| Transgender Persons | 9 | 2019 | 322 | 2.76 | Why? |
| Syphilis Serodiagnosis | 6 | 2019 | 30 | 2.64 | Why? |
| HIV Infections | 35 | 2019 | 11620 | 2.54 | Why? |
| Treponema pallidum | 4 | 2018 | 42 | 2.28 | Why? |
| Sexual Partners | 10 | 2019 | 612 | 2.14 | Why? |
| Drug Resistance, Bacterial | 8 | 2019 | 1414 | 2.05 | Why? |
| Antibodies, Bacterial | 6 | 2018 | 510 | 1.65 | Why? |
| Trichomonas vaginalis | 8 | 2019 | 19 | 1.56 | Why? |
| Mass Screening | 18 | 2021 | 8005 | 1.52 | Why? |
| Anti-Bacterial Agents | 16 | 2019 | 10083 | 1.52 | Why? |
| Genotyping Techniques | 4 | 2019 | 360 | 1.50 | Why? |
| Microbial Sensitivity Tests | 6 | 2019 | 2886 | 1.44 | Why? |
| Los Angeles | 9 | 2021 | 647 | 1.38 | Why? |
| Rectum | 4 | 2019 | 495 | 1.35 | Why? |
| Pharynx | 4 | 2018 | 1544 | 1.30 | Why? |
| Sexual and Gender Minorities | 6 | 2019 | 1019 | 1.24 | Why? |
| Circumcision, Male | 3 | 2017 | 57 | 1.15 | Why? |
| Patient Acceptance of Health Care | 11 | 2019 | 5002 | 1.03 | Why? |
| Pre-Exposure Prophylaxis | 3 | 2018 | 1138 | 1.00 | Why? |
| Point-of-Care Systems | 6 | 2018 | 2955 | 1.00 | Why? |
| Patient Preference | 3 | 2019 | 750 | 0.97 | Why? |
| Sexual Behavior | 8 | 2019 | 1322 | 0.96 | Why? |
| Immunoassay | 4 | 2018 | 4485 | 0.95 | Why? |
| Sexually Transmitted Diseases, Bacterial | 2 | 2019 | 26 | 0.93 | Why? |
| Mycoplasma Infections | 2 | 2019 | 65 | 0.92 | Why? |
| AIDS Serodiagnosis | 2 | 2019 | 64 | 0.90 | Why? |
| Cephalosporins | 3 | 2017 | 250 | 0.83 | Why? |
| Penicillin G Benzathine | 1 | 2019 | 14 | 0.80 | Why? |
| Mycoplasma genitalium | 2 | 2019 | 30 | 0.80 | Why? |
| Peru | 10 | 2019 | 1010 | 0.80 | Why? |
| Proctitis | 1 | 2019 | 16 | 0.80 | Why? |
| HIV Antibodies | 4 | 2018 | 776 | 0.78 | Why? |
| Chlamydia | 1 | 2018 | 47 | 0.75 | Why? |
| Metronidazole | 1 | 2018 | 59 | 0.75 | Why? |
| Diagnostic Tests, Routine | 3 | 2018 | 2643 | 0.73 | Why? |
| Encephalitis Virus, St. Louis | 1 | 2017 | 3 | 0.73 | Why? |
| Encephalitis, St. Louis | 1 | 2017 | 3 | 0.73 | Why? |
| Lymphogranuloma Venereum | 1 | 2018 | 23 | 0.72 | Why? |
| Bronchopneumonia | 1 | 2017 | 29 | 0.71 | Why? |
| Hepatitis C | 3 | 2019 | 1514 | 0.71 | Why? |
| Smartphone | 3 | 2018 | 1840 | 0.71 | Why? |
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 21 | 0.70 | Why? |
| Pregnancy Complications, Infectious | 14 | 2019 | 11559 | 0.70 | Why? |
| Coxiella burnetii | 1 | 2018 | 120 | 0.69 | Why? |
| California | 7 | 2021 | 2047 | 0.69 | Why? |
| HIV | 4 | 2019 | 1116 | 0.68 | Why? |
| Aortitis | 1 | 2017 | 39 | 0.68 | Why? |
| Genotype | 6 | 2019 | 4697 | 0.68 | Why? |
| Meningitis, Bacterial | 1 | 2018 | 111 | 0.66 | Why? |
| Anti-HIV Agents | 4 | 2018 | 2209 | 0.66 | Why? |
| HIV-2 | 1 | 2017 | 92 | 0.66 | Why? |
| Postal Service | 1 | 2017 | 88 | 0.66 | Why? |
| Lymphoma, Mantle-Cell | 1 | 2017 | 109 | 0.66 | Why? |
| Q Fever | 1 | 2018 | 130 | 0.64 | Why? |
| Diagnostic Self Evaluation | 2 | 2017 | 394 | 0.63 | Why? |
| Prenatal Diagnosis | 1 | 2019 | 345 | 0.62 | Why? |
| Nucleic Acid Amplification Techniques | 6 | 2019 | 3388 | 0.61 | Why? |
| Metagenome | 1 | 2017 | 268 | 0.58 | Why? |
| Immunoenzyme Techniques | 1 | 2017 | 448 | 0.57 | Why? |
| African Americans | 4 | 2019 | 3363 | 0.57 | Why? |
| Anal Canal | 1 | 2017 | 367 | 0.55 | Why? |
| Geographic Information Systems | 1 | 2018 | 507 | 0.53 | Why? |
| Sensitivity and Specificity | 16 | 2021 | 22971 | 0.52 | Why? |
| San Francisco | 5 | 2019 | 711 | 0.52 | Why? |
| Endocarditis, Bacterial | 1 | 2018 | 344 | 0.50 | Why? |
| Stillbirth | 1 | 2018 | 544 | 0.50 | Why? |
| Poverty | 4 | 2021 | 2302 | 0.50 | Why? |
| Humans | 103 | 2021 | 930598 | 0.50 | Why? |
| Hepacivirus | 2 | 2019 | 1509 | 0.49 | Why? |
| Point-of-Care Testing | 5 | 2019 | 2782 | 0.49 | Why? |
| Positron-Emission Tomography | 1 | 2017 | 802 | 0.46 | Why? |
| Asymptomatic Diseases | 2 | 2021 | 3444 | 0.46 | Why? |
| Specimen Handling | 5 | 2021 | 6190 | 0.45 | Why? |
| Social Networking | 1 | 2018 | 737 | 0.45 | Why? |
| Text Messaging | 1 | 2016 | 389 | 0.44 | Why? |
| Young Adult | 26 | 2021 | 93724 | 0.44 | Why? |
| Bacterial Proteins | 2 | 2017 | 1318 | 0.43 | Why? |
| Pregnant Women | 4 | 2018 | 2535 | 0.41 | Why? |
| Epidemics | 2 | 2021 | 6407 | 0.38 | Why? |
| Unsafe Sex | 3 | 2019 | 139 | 0.38 | Why? |
| Male | 47 | 2021 | 367725 | 0.38 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2019 | 11367 | 0.38 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.38 | Why? |
| Premature Birth | 2 | 2018 | 2151 | 0.38 | Why? |
| United States | 15 | 2021 | 46150 | 0.37 | Why? |
| Prevalence | 17 | 2021 | 25773 | 0.37 | Why? |
| Patient Education as Topic | 1 | 2018 | 1476 | 0.36 | Why? |
| Adult | 42 | 2021 | 244371 | 0.36 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.36 | Why? |
| Contact Tracing | 4 | 2020 | 8448 | 0.35 | Why? |
| Female | 51 | 2021 | 380317 | 0.34 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.33 | Why? |
| Social Marketing | 1 | 2006 | 47 | 0.33 | Why? |
| Adolescent | 21 | 2021 | 86841 | 0.32 | Why? |
| Online Systems | 1 | 2008 | 240 | 0.32 | Why? |
| Azithromycin | 2 | 2018 | 3943 | 0.31 | Why? |
| Pregnancy | 16 | 2019 | 23879 | 0.31 | Why? |
| Cephalosporin Resistance | 2 | 2017 | 12 | 0.31 | Why? |
| Botswana | 4 | 2019 | 98 | 0.31 | Why? |
| Bisexuality | 1 | 2006 | 119 | 0.31 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.31 | Why? |
| Research Personnel | 1 | 2016 | 1037 | 0.30 | Why? |
| Ceftriaxone | 2 | 2018 | 365 | 0.29 | Why? |
| Feasibility Studies | 4 | 2019 | 3467 | 0.29 | Why? |
| Early Detection of Cancer | 1 | 2017 | 1956 | 0.29 | Why? |
| Asian Americans | 2 | 2021 | 387 | 0.29 | Why? |
| Herpesvirus 2, Human | 2 | 2009 | 137 | 0.28 | Why? |
| Ambulatory Care | 2 | 2018 | 4947 | 0.27 | Why? |
| Herpes Genitalis | 1 | 2004 | 90 | 0.27 | Why? |
| DNA, Bacterial | 2 | 2018 | 835 | 0.26 | Why? |
| Asymptomatic Infections | 3 | 2019 | 7218 | 0.26 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.26 | Why? |
| Vietnam | 2 | 2019 | 1665 | 0.26 | Why? |
| Focus Groups | 2 | 2017 | 811 | 0.25 | Why? |
| Mobile Applications | 1 | 2018 | 3032 | 0.24 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.24 | Why? |
| Public Health | 5 | 2021 | 16359 | 0.23 | Why? |
| Child Abuse | 1 | 2009 | 504 | 0.23 | Why? |
| Time Factors | 6 | 2021 | 31397 | 0.23 | Why? |
| Ambulatory Care Facilities | 4 | 2019 | 2063 | 0.23 | Why? |
| Polymerase Chain Reaction | 3 | 2021 | 6740 | 0.21 | Why? |
| Students | 1 | 2019 | 5255 | 0.21 | Why? |
| Prenatal Care | 4 | 2019 | 1314 | 0.21 | Why? |
| Mosaicism | 2 | 2017 | 44 | 0.21 | Why? |
| Trichomonas Vaginitis | 1 | 2019 | 7 | 0.20 | Why? |
| Self Disclosure | 1 | 2019 | 12 | 0.20 | Why? |
| Syphilis, Latent | 1 | 2019 | 1 | 0.20 | Why? |
| Social Media | 2 | 2019 | 5798 | 0.20 | Why? |
| Chorioretinitis | 1 | 2019 | 6 | 0.20 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.20 | Why? |
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 8811 | 0.19 | Why? |
| Risk-Taking | 3 | 2017 | 508 | 0.19 | Why? |
| Hepatitis C Antibodies | 1 | 2019 | 120 | 0.19 | Why? |
| Florida | 1 | 2021 | 598 | 0.19 | Why? |
| Remission, Spontaneous | 1 | 2019 | 186 | 0.19 | Why? |
| Pregnancy, Unplanned | 1 | 2018 | 36 | 0.18 | Why? |
| Glycerophospholipids | 1 | 2017 | 12 | 0.18 | Why? |
| RNA, Ribosomal, 16S | 2 | 2019 | 793 | 0.18 | Why? |
| RNA, Bacterial | 1 | 2018 | 116 | 0.18 | Why? |
| Confidentiality | 2 | 2017 | 581 | 0.18 | Why? |
| Clinical Laboratory Techniques | 3 | 2021 | 23402 | 0.18 | Why? |
| Gastrodia | 1 | 2017 | 1 | 0.18 | Why? |
| Transsexualism | 1 | 2017 | 43 | 0.18 | Why? |
| Eye Infections, Bacterial | 1 | 2019 | 86 | 0.17 | Why? |
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 136 | 0.17 | Why? |
| House Calls | 1 | 2020 | 215 | 0.17 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.17 | Why? |
| Health Services Accessibility | 2 | 2018 | 10697 | 0.17 | Why? |
| Grounded Theory | 1 | 2017 | 48 | 0.17 | Why? |
| Reagent Kits, Diagnostic | 2 | 2018 | 2149 | 0.17 | Why? |
| Philadelphia | 1 | 2019 | 454 | 0.17 | Why? |
| Cervix Uteri | 1 | 2018 | 146 | 0.17 | Why? |
| Directive Counseling | 1 | 2017 | 77 | 0.17 | Why? |
| Haiti | 1 | 2017 | 175 | 0.16 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.16 | Why? |
| Condoms | 1 | 2018 | 235 | 0.16 | Why? |
| Insurance Coverage | 1 | 2021 | 348 | 0.16 | Why? |
| Urine | 1 | 2019 | 469 | 0.16 | Why? |
| Qualitative Research | 3 | 2019 | 4337 | 0.16 | Why? |
| Men's Health | 1 | 2017 | 80 | 0.16 | Why? |
| Demography | 2 | 2021 | 1660 | 0.16 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.15 | Why? |
| Practice Guidelines as Topic | 3 | 2018 | 15421 | 0.15 | Why? |
| Codon | 1 | 2017 | 287 | 0.15 | Why? |
| Anus Neoplasms | 1 | 2017 | 123 | 0.15 | Why? |
| Chromatography, Affinity | 1 | 2017 | 310 | 0.15 | Why? |
| Prescriptions | 1 | 2017 | 258 | 0.15 | Why? |
| Doxycycline | 1 | 2018 | 307 | 0.15 | Why? |
| Microbiological Techniques | 1 | 2017 | 232 | 0.15 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.15 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.15 | Why? |
| Genome, Viral | 1 | 2017 | 13157 | 0.15 | Why? |
| Insurance, Health | 1 | 2021 | 634 | 0.15 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.14 | Why? |
| Confidence Intervals | 1 | 2017 | 744 | 0.14 | Why? |
| Family Planning Services | 1 | 2018 | 236 | 0.14 | Why? |
| Health Services Research | 2 | 2018 | 756 | 0.14 | Why? |
| False Negative Reactions | 1 | 2021 | 1785 | 0.14 | Why? |
| Multimodal Imaging | 1 | 2019 | 534 | 0.14 | Why? |
| Evidence-Based Medicine | 1 | 2007 | 3228 | 0.13 | Why? |
| Alleles | 2 | 2017 | 1557 | 0.13 | Why? |
| Molecular Diagnostic Techniques | 3 | 2019 | 4239 | 0.13 | Why? |
| Saliva | 2 | 2021 | 4679 | 0.13 | Why? |
| Macrolides | 1 | 2017 | 369 | 0.13 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.13 | Why? |
| Costs and Cost Analysis | 1 | 2018 | 694 | 0.12 | Why? |
| Mutation | 3 | 2018 | 12376 | 0.12 | Why? |
| Interviews as Topic | 2 | 2017 | 1952 | 0.12 | Why? |
| Cohort Studies | 5 | 2018 | 36005 | 0.12 | Why? |
| Colonoscopy | 1 | 2019 | 738 | 0.12 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.12 | Why? |
| Reproducibility of Results | 3 | 2018 | 11304 | 0.12 | Why? |
| Infectious Disease Transmission, Vertical | 3 | 2018 | 5164 | 0.12 | Why? |
| Video Recording | 1 | 2018 | 786 | 0.12 | Why? |
| Gestational Age | 1 | 2018 | 1488 | 0.12 | Why? |
| Hong Kong | 1 | 2021 | 3361 | 0.12 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.12 | Why? |
| Nasopharynx | 2 | 2021 | 10224 | 0.11 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.11 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.11 | Why? |
| Drug Utilization | 1 | 2017 | 619 | 0.11 | Why? |
| Attitude to Health | 1 | 2004 | 2002 | 0.11 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.11 | Why? |
| Cytomegalovirus Infections | 1 | 2017 | 667 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Cross-Sectional Studies | 9 | 2021 | 53120 | 0.11 | Why? |
| Personal Satisfaction | 1 | 2020 | 1243 | 0.10 | Why? |
| New York | 1 | 2018 | 2488 | 0.10 | Why? |
| Rural Health Services | 1 | 2017 | 496 | 0.10 | Why? |
| Risk Factors | 9 | 2020 | 71621 | 0.10 | Why? |
| Alcoholism | 1 | 2017 | 691 | 0.10 | Why? |
| Intention | 1 | 2019 | 1380 | 0.10 | Why? |
| Employment | 1 | 2021 | 1754 | 0.10 | Why? |
| Aged | 8 | 2021 | 215776 | 0.10 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.10 | Why? |
| Limit of Detection | 1 | 2017 | 2698 | 0.10 | Why? |
| Genome, Bacterial | 1 | 2012 | 446 | 0.09 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.09 | Why? |
| Social Stigma | 1 | 2017 | 1049 | 0.09 | Why? |
| Prospective Studies | 6 | 2019 | 43301 | 0.09 | Why? |
| Retrospective Studies | 6 | 2019 | 105322 | 0.09 | Why? |
| Fatal Outcome | 1 | 2017 | 3438 | 0.09 | Why? |
| New York City | 1 | 2021 | 7432 | 0.08 | Why? |
| Congresses as Topic | 1 | 2017 | 1347 | 0.08 | Why? |
| Antibodies, Viral | 2 | 2018 | 51949 | 0.08 | Why? |
| Virus Shedding | 2 | 2021 | 5834 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
| Health Surveys | 2 | 2009 | 2841 | 0.08 | Why? |
| Vagina | 2 | 2019 | 327 | 0.08 | Why? |
| Medical Audit | 1 | 2007 | 218 | 0.08 | Why? |
| Family Relations | 1 | 2009 | 288 | 0.08 | Why? |
| Alcohol Drinking | 1 | 2017 | 1663 | 0.07 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3633 | 0.07 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2019 | 2654 | 0.07 | Why? |
| Genomics | 1 | 2017 | 3118 | 0.07 | Why? |
| Surveys and Questionnaires | 3 | 2019 | 43792 | 0.07 | Why? |
| Infant, Newborn | 4 | 2018 | 23105 | 0.07 | Why? |
| Universities | 1 | 2019 | 4374 | 0.07 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| South Africa | 3 | 2018 | 3326 | 0.06 | Why? |
| Family | 1 | 2017 | 2909 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.06 | Why? |
| Primary Health Care | 2 | 2018 | 4839 | 0.06 | Why? |
| Viral Load | 3 | 2018 | 15850 | 0.06 | Why? |
| Social Support | 1 | 2017 | 3183 | 0.06 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.06 | Why? |
| Domestic Violence | 1 | 2009 | 522 | 0.06 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.06 | Why? |
| Pediatrics | 1 | 2017 | 2969 | 0.05 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.05 | Why? |
| Phylogeny | 2 | 2017 | 13341 | 0.05 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.05 | Why? |
| RNA, Ribosomal, 23S | 1 | 2019 | 25 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Internet | 1 | 2018 | 6204 | 0.05 | Why? |
| Africa, Southern | 1 | 2019 | 78 | 0.05 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.05 | Why? |
| Urethra | 1 | 2019 | 47 | 0.05 | Why? |
| Ophthalmoscopy | 1 | 2019 | 65 | 0.05 | Why? |
| Sex Work | 1 | 2019 | 96 | 0.05 | Why? |
| Directly Observed Therapy | 1 | 2017 | 34 | 0.04 | Why? |
| Contraception Behavior | 1 | 2018 | 60 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.04 | Why? |
| Optical Imaging | 1 | 2019 | 197 | 0.04 | Why? |
| Professional Staff Committees | 1 | 2017 | 94 | 0.04 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 13720 | 0.04 | Why? |
| Child | 2 | 2021 | 70012 | 0.04 | Why? |
| Women's Health | 1 | 2002 | 444 | 0.04 | Why? |
| Clinical Studies as Topic | 1 | 2017 | 118 | 0.04 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.04 | Why? |
| Aged, 80 and over | 3 | 2019 | 88759 | 0.04 | Why? |
| Substance-Related Disorders | 1 | 2009 | 2038 | 0.03 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.03 | Why? |
| Africa South of the Sahara | 1 | 2019 | 1335 | 0.03 | Why? |
| Hydroxychloroquine | 1 | 2018 | 12447 | 0.03 | Why? |
| Rural Health | 1 | 2017 | 243 | 0.03 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.03 | Why? |
| Reference Standards | 1 | 2017 | 1163 | 0.03 | Why? |
| Contig Mapping | 1 | 2012 | 5 | 0.03 | Why? |
| Gene Transfer, Horizontal | 1 | 2012 | 64 | 0.03 | Why? |
| Logistic Models | 1 | 2006 | 9089 | 0.03 | Why? |
| RNA, Viral | 1 | 2019 | 32276 | 0.03 | Why? |
| Sexual Health | 1 | 2017 | 419 | 0.03 | Why? |
| Tomography, Optical Coherence | 1 | 2019 | 1008 | 0.03 | Why? |
| Serologic Tests | 1 | 2004 | 4359 | 0.03 | Why? |
| Temperature | 1 | 2019 | 2305 | 0.02 | Why? |
| Biological Specimen Banks | 1 | 2017 | 1142 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 7868 | 0.02 | Why? |
| Health Behavior | 1 | 2006 | 4449 | 0.02 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Mental Disorders | 1 | 2009 | 6742 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| Child, Preschool | 1 | 2009 | 36283 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| Laboratories | 1 | 2017 | 2858 | 0.02 | Why? |
| Socioeconomic Factors | 2 | 2017 | 8495 | 0.02 | Why? |
| Canada | 1 | 2017 | 6018 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2012 | 2830 | 0.02 | Why? |
| Leadership | 1 | 2017 | 2241 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Social Class | 1 | 2009 | 1360 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Brazil | 1 | 2017 | 12582 | 0.01 | Why? |
| India | 1 | 2017 | 11875 | 0.01 | Why? |
| Urban Population | 1 | 2009 | 2000 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.01 | Why? |
| Substance Abuse, Intravenous | 1 | 2002 | 411 | 0.01 | Why? |
| Cities | 1 | 2009 | 4937 | 0.01 | Why? |
| Risk Assessment | 1 | 2001 | 25439 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Europe | 1 | 2012 | 12702 | 0.01 | Why? |
| Infant | 1 | 2018 | 30274 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Health Personnel | 1 | 2004 | 29646 | 0.01 | Why? |
| Data Collection | 1 | 2002 | 1769 | 0.01 | Why? |
| Minority Groups | 1 | 2002 | 1631 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2002 | 5440 | 0.01 | Why? |